The 12 most recent market catalysts affecting $XRTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Neutral
Impact 55
XORTX Therapeutics Completes Manufacturing and Packaging of Clinical Drug Supply for XRX-OXY-102 Trial
XORTX Therapeutics has completed the manufacturing and packaging of its clinical drug supply for the XRX-OXY-102 trial. This milestone is crucial as it fulfills a prerequisite for …
Nov 15, 2026
Corporate Catalyst
Bullish
Impact 60
Japan Patent Office Grants Patent for XORTX Therapeutics' XRx-101 Program
XORTX Therapeutics announced that the Japan Patent Office has decided to grant a patent for its XRx-101 program, specifically for compositions and formulations using xanthine oxida…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 75
XORTX Therapeutics shares are trading higher after the company announced an outline of its anticipated Clinical Trial Application submission to Health Canada for the XRx-026 gout program.
This headline indicates a positive corporate catalyst for XORTX Therapeutics. The announcement of an anticipated Clinical Trial Application (CTA) submission to Health Canada for th…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 75
XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
XORTX Therapeutics announced a significant step forward for its gout drug candidate, XRx-026, by preparing a Clinical Trial Application (CTA) with Health Canada. This move is cruci…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 75
XORTX Therapeutics shares are trading higher after the company announced an outline of its anticipated Clinical Trial Application submission to Health Canada for the XRx-026 gout program.
The headline indicates a significant corporate catalyst for XORTX Therapeutics. The announcement of an anticipated Clinical Trial Application submission to Health Canada for a new …
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 75
XORTX Therapeutics Plans Health Canada Clinical Trial Application For Gout Drug XORLO Ahead Of Planned FDA Filing
The planned Health Canada Clinical Trial Application for XORLO is a crucial milestone for XORTX Therapeutics. It indicates progress in the regulatory pathway for their gout drug, p…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
XORTX Therapeutics shares are trading higher after the company outlined its anticipated IND application submission to the FDA for the XRx-026 gout program.
This headline represents a significant corporate catalyst for XORTX Therapeutics. The submission of an IND application is a critical milestone in drug development, indicating progr…
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 65
XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program
XORTX Therapeutics is outlining its strategic path for the XRx-026 gout program, including an anticipated IND submission to the FDA in Q4 2026. This is a significant step in the dr…
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 75
XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know
XORTX Therapeutics has initiated the manufacturing of drug material and tablets for XORLO, its proprietary oxypurinol formulation for gout. This is a significant step as it directl…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 85
XORTX Therapeutics shares are trading higher after the company announced the launch of production of drug material and tablet manufacturing to support its XRx-026 program for the treatment of gout.
The launch of drug material and tablet manufacturing is a critical milestone for any pharmaceutical company, especially for a clinical-stage biotech like XORTX. It de-risks the dev…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 65
XORTX Therapeutics Starts Production Of Drug, Tablet Manufacturing For Its XRx-026 Trial To Treat Gout
XORTX Therapeutics has initiated the production of drug material and tablet manufacturing for its XRx-026 program, which is a proprietary formulation of oxypurinol for gout treatme…
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 65
XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency
XORTX Therapeutics has terminated and postponed its investor relations and marketing agreement, recovering a significant $2.5 million payment. This decision is directly linked to t…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.